Physician profile
Claire E Veltkamp
NPI 1649641135
$1,553.44
in general payments reported to CMS, 2019-2025
21 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $189 · 2023: $857 · 2024: $174 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $270.67 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $206.43 | 2022-2024 | Repatha, Evenity, Prolia |
| Edwards Lifesciences Corporation | $192.23 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $145.85 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $136.47 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $76.52 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $70.13 | 2023-2025 | Spravato |
| Pfizer INC. | $58.89 | 2023 | |
| Organon LLC | $58.73 | 2023 | Nexplanon |
| Glaxosmithkline, LLC. | $54.50 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $48.56 | 2024-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $47.87 | 2025 | Capvaxive, Vaxneuvance, Rotateq |
| Exact Sciences Corporation | $32.79 | 2023-2025 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $30.68 | 2023 | Xarelto |
| Tactile Systems Technology INC | $26.79 | 2025 | Flexitouch Plus, Nimbl |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.98 | 2024 | |
| Dexcom, INC. | $18.03 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $15.31 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $15.09 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $14.90 | 2023 | |
| Renalytix Ai, INC. | $14.02 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Veltkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.